You are here:

trifluridine/tipiracil (Lonsurf)

Advice

following a full submission assessed under the end-of-life and orphan-equivalent process

trifluridine/tipiracil (Lonsurf®) is accepted for use within NHS Scotland.

Indication under review: The treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.

Treatment with trifluridine/tipiracil was associated with an improvement in overall survival when compared with best supportive care in patients who had received, or were intolerant of, first and second-line therapies for metastatic CRC.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of trifluridine/tipiracil. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: trifluridine/tipiracil (Lonsurf)
SMC Drug ID: 1221/17
Manufacturer: Servier Laboratories Ltd
Indication: for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 February 2017

Back